Please find attached herewith Notice convening the 15th Annual General Meeting.

August 11, 2026 To, To, Dy. General Manager The Manager - Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref: Scrip Name: ALIVUS Dear Sirs, Sub: Notice of 15th Annual General Meeting of the Company for FY 2025-26 as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Further to our letter dated August 6, 2026 and pursuant to Regulation 30 of the Listing Regulations, enclosed please find herewith the Notice and Explanatory Statement convening the 15th Annual General Meeting (AGM) scheduled to be held on Tuesday, September 8, 2026 at 3.00 p.m. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The notice of AGM is being sent to all the members whose e-mail ids have been registered with the Company. The Company is pleased to provide to its members the facility to exercise their right to vote on the resolutions proposed to be passed at the AGM by electronic means. Only Shareholders whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e. Tuesday, September 1, 2026, shall be entitled to avail the e-voting facility. The remote e-voting facility commences on Friday, September 4, 2026 from 9.00 a.m. (IST) and ends on Monday, September 7, 2026 at 5.00 p.m. (IST). This is for your information and records. Thanking you Yours faithfully, For Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) Rudalf Corriea Company Secretary & Compliance Officer Encl.: As above Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited ) Corporate Office: Registered Office: Technopolis Knowledge Park, A wingO, ffice No. 401 to 407, Plot No 170-172, Chandramouli Industrial Estate 4th Floor, Mahakali Caves Road, Andheri E(), Mumbai– 400093 Mohol Bazarpeth, Solapur 413 213, India T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@alivus.com | W: www.alivus.com Alivus Life Sciences Limited | 1 ALIVUS LIFE SCIENCES LIMITED (formerly Glenmark Life Sciences Limited) Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413213, Maharashtra Corporate Office: Technopolis Knowledge Park, A Wing, Office No. 401 to 407, 4th Floor, Mahakali Caves Road, Andheri (E), Mumbai 400093 Tel No: 91 22 6829 7979; CIN: L74900PN2011PLC139963 Website: www.alivus.com; Email: complianceofficer@alivus.com Notice is hereby given that the fifteenth Annual General of the Company and being eligible, has offered himself Meeting (“AGM”) of the Company will be held on Tuesday, for re-appointment be and is hereby re-appointed as 8 September 2026, at 3.00 p.m. through Video Conferencing a Non-Executive Director of the Company, liable to (“VC”) / Other Audio Visual Means (“OAVM”), to transact the retire by rotation.” following business: SPECIAL BUSINESS: ORDINARY BUSINESS: 4. To ratify the remuneration payable to Cost Auditors 1. To receive, consider, approve and adopt the Audited of the Company for the financial year ending Financial Statements for the Financial Year ended 31 March 2027 and, in this regard, to consider and 31 March 2026 together with the reports of the Board if thought fit, to pass the following resolution as an and Auditors thereon and, in this regard, to consider Ordinary Resolution: and if thought fit, to pass the following resolution as “RESOLVED THAT pursuant to Section 148 and other an Ordinary Resolution: applicable provisions, if any, of the Companies Act, “RESOLVED THAT the Audited Financial Statements 2013 and the Companies (Audit and Auditors) Rules, for the Financial Year ended 31 March 2026 and 2014 (including any statutory modification(s) or the Reports of Board of Directors and the Auditors re-enactment(s) thereof, for the time being in force), thereon be and the same are hereby received, the remuneration of ` 0.50 million plus applicable considered and adopted.” taxes and reimbursement of actual travel and out of pocket expenses as approved by the Board of 2. To declare the final dividend on equity shares for Directors of the Company to be paid to Kirit Mehta & the financial year ended 31 March 2026 and, in this Co. LLP, Cost Auditors of the Company for the conduct regard, to consider and if thought fit, to pass the of audit of Company’s cost records for the financial following resolution as an Ordinary Resolution: year ending 31 March 2027, be and is hereby ratified “RESOLVED THAT approval be and is hereby and confirmed.” accorded for declaration and payment of final By Order of the Board dividend of ` 5 (Rupees Five only) per equity share For Alivus Life Sciences Limited of the face value of ` 2 (Rupees Two) each fully (formerly Glenmark Life Sciences Limited) paid up, of the Company, as recommended by the Board of Directors for the financial year ended Rudalf Corriea 31 March 2026.” Company Secretary & Compliance Officer 3. To appoint a Director in place of Mr. Hiren Patel ACS 27911 (DIN: 00145149) who retires by rotation and being eligible, offers himself for re-appointment as per Registered Office: Section 152(6) of the Companies Act, 2013 and, in Plot No. 170-172, this regard, to consider and if thought fit, to pass the Chandramouli Industrial Estate, following resolution as an Ordinary Resolution: Mohol Bazarpeth, Solapur 413213, “RESOLVED THAT pursuant to the provisions of the Maharashtra Companies Act, 2013 and the Rules made thereunder, Mr. Hiren Patel (DIN: 00145149), aged 53 years, a Place: Mumbai Non-Executive Director of the Company, who is liable Date: 30 July 2026 to retire by rotation at this Annual General Meeting NOTES complianceofficer@alivus.com, by providing their shareholding details. 1. The relative Explanatory Statement, pursuant to Section 102 of the Companies Act, 2013 (‘the Act’), 6. Members will be provided with a facility of electronic in respect of the business set out in item No. 4 above voting (e-voting) and for attending the AGM through and the relevant details of the Director seeking VC/OAVM by the National Securities Depository re-appointment under item No. 3 above as required Limited (NSDL) e-Voting system i.e. www.evoting. by Regulation 36(3) of the Securities and Exchange nsdl.com. Board of India (Listing Obligations and Disclosure 7. Since this AGM is being held pursuant to the Requirements) Regulations, 2015 (‘SEBI Listing Circulars through VC/OAVM, physical attendance Regulations’) and as required under Secretarial of Members at the venue of the AGM has been Standard on General Meetings (SS-2) issued by The dispensed with. Further, as per the SEBI Listing Institute of Company Secretaries of India, is annexed Regulations, requirement to send proxy forms shall hereto. not be applicable to AGM held only through electronic 2. In accordance with the provisions of the Act read mode. Accordingly, the facility for appointment of with the Rules made thereunder and General Circular proxies by the Members will not be available for this No. 03/2025 dated 22 September 2025, including AGM and hence the Proxy Form and Attendance Slip other circulars issued in this regard by the Ministry are not annexed to this Notice. of Corporate Affairs (“MCA”) from time to time (“the 8. Members can login and join 30 (Thirty) minutes prior Circulars”), companies are allowed to hold AGM to the scheduled time of meeting and window for through Video Conference or Other Audio Visual joining shall be kept open till conclusion of the AGM. Means (“VC/OAVM”) till further orders, without the physical presence of members at a common venue. 9. Members attending the AGM through VC/OAVM Accordingly, the AGM of the Company is being held shall be counted for the purpose of reckoning the through VC/OAVM. The deemed venue for AGM quorum un [Showing first 8,000 characters — download PDF for full document]